Position of the Transparency Council – Libtayo (cemiplimab)

At its meeting on 25 November 2024, the Transparency Council adopted position No. 130/2024 on the evaluation of the drug Libtayo (cemiplimab) in the framework of the drug programme B.6. “Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)”

Publication of the position >>